Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Considering a career with us?

Mercury Pharmaceuticals is a dynamic and entrepreneurial team. We are inspired by the passionate commitment to make a positive difference in the lives of patients.

Current open positions:

  • Senior Scientist with broad experience in preclinical drug discovery
  • Postdoctoral Scientist with an aptitude to perform experimental protocols and procedures, including detailed data collection, analysis, operation and knowledge of safety standards and maintenance of specialized equipment.
  • Research Associate with broad a experience and Understanding of general research objectives.Working knowledge of database management, personal computers, and presentation and imaging software. Understanding of general research objectives. Familiar with routine laboratory procedures and experimental protocols. Must possess computer skills to include, but not limited to, Excel and Word.

Please email resumes to: hr@mercurypharms.com

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

STAY INFORMED!

Physical activity declines after starting GLP-1 obesity treatments

14

Jun 2026

Physical activity declines after starting GLP-1 obesity treatments

Adults with obesity losing weight with glucagon-like peptide-1 (GLP-1) receptor agonist medications significantly decreased their physical activity, which is essential to protect muscle, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

READ MORE
AI model could improve screening for primary aldosteronism

14

Jun 2026

AI model could improve screening for primary aldosteronism

A study of a new AI model examining 30 years of routine electronic health records (EHR) data could improve screening for primary aldosteronism, a leading cause of high blood pressure that is often unrecognized but increases patients' risk of cardiovascular complications, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

READ MORE

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.